Keros Therapeutics, Inc. (KROS) — SC 13G/A Filings
All SC 13G/A filings from Keros Therapeutics, Inc.. Browse 3 SC 13G/A reports with AI-powered summaries and risk analysis.
SC 13G/A Filings (3)
- SC 13G/A Filing — Feb 13, 2024
-
FMR LLC & Abigail Johnson Maintain 12.93% Stake in Keros Therapeutics
— Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its Chair and CEO, Abigail P. Johnson, have updated their ownership stake in Keros Therapeutics, Inc. (NASDAQ: KROS) to 12 -
BlackRock Amends Keros Therapeutics Stake, Passive Investment
— Jan 26, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating a change in its ownership of Keros Therapeutics, Inc. common stock as of December
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX